If this is your first visit, be sure to check out the FAQ in HCMA Announcements. You may have to register before you can post: click the register link above to proceed. To start viewing messages, select the forum that you want to visit from the selection below. Your Participation in this message board is strictly voluntary. Information and comments on the message board do not necessarily reflect the feelings, opinions, or positions of the Hypertrophic Cardiomyopathy Association. At no time should participants to this board substitute information within for individual medical advice. The Hypertrophic Cardiomyopathy Association shall not be liable for any information provided herein. All participants in this board should conduct themselves in a professional and respectful manner. Failure to do so will result in suspension or termination. The moderators of the message board working with the HCMA will be responsible for notifying participants if they have violated the rules of conduct for the board. Moderators or HCMA staff may edit any post to ensure it conforms with the rules of the board or may delete it. This community is welcoming to all those with HCM we ask that you remember each user comes to the board with information and a point of view that may differ from that which you hold, respect is critical, please post respectfully. Thank you


No announcement yet.

HEADLINE: Conditions: Cardiomyopathy


About the Author


hcma Find out more about hcma
  • Filter
  • Time
  • Show
Clear All
new posts

  • HEADLINE: Conditions: Cardiomyopathy

    Copyright 2003 Times Newspapers Limited
    The Times (London)

    November 3, 2003, Monday

    SECTION: Features; Hospital Consultants Guide 8

    LENGTH: 1443 words

    HEADLINE: Conditions: Cardiomyopathy


    THIS IS the term used to describe any disease which affects the heart

    There are four main forms - dilated cardiomyopathy (DCM), hypertrophic
    cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC) and
    restrictive cardiomyopathy (RCM).

    Dilated cardiomyopathy: The heart becomes enlarged and pumps less strongly.
    The heart muscle becomes weak, thin or floppy and is unable to pump blood
    efficiently, leading to heart failure (see page 6). The condition is often
    genetic and is diagnosed when other causes of heart failure, such as coronary
    artery disease, hypertension and valve disease, have been excluded.

    Hypertrophic cardiomyopathy: This is characterised by an excessive
    thickening of the heart muscle. The cardiac muscle cells are usually aligned in
    parallel lines but here the cells become disorganised. These changes in the
    structure of the heart may cause rhythm disturbances and sudden death.

    Arrhythmogenic right ventricular cardiomyopathy: The heart muscle is
    replaced by fibrous scar and fatty tissue. This is patchy in distribution, so
    abnormal areas may be surrounded by normal ones. The right ventricle (lower
    heart chamber) tends to be most affected. It is thought that abnormal genes lead
    to heart muscle degeneration and that fibrous and fatty tissue replaces these
    heart muscle cells in an attempt by the body to repair the damage. The
    disorganised structure leads to abnormal electrical activity which causes rhythm
    disturbances and sudden death.

    Restrictive cardiomyopathy: This occurs when the walls of the ventricles are
    stiff and prevent the normal filling with blood. The causes are unknown,
    although it can be secondary to rare metabolic disorders.

    Most cardiomyopathies are inherited - if either parent is affected you have
    a 50 per cent chance of inheriting the abnormal gene implicated. "It used to be
    thought that dilated cardiomyopathy could be caused by pregnancy and excessive
    alcohol intake, but now it is recognised that putting extra stress on the heart
    unmasks the underlying genetic defect," explains Bill McKenna, professor of
    cardiology at the Heart Hospital, London.

    Symptoms and severity of cardiomyopathy vary with the patient. Some have few
    or no symptoms, while others develop problems such as heart failure (where the
    muscle is not strong enough to pump blood around the body), abnormal rhythms,
    and blood clots (from the slowing of blood flow). Common symptoms include
    shortness of breath, chest pains - usually brought on by physical exertion -
    palpitations and light-headedness or blackouts. But for some, the first
    indication of a problem comes too late - unexpected sudden death in the young is
    usually ascribed to abnormalities of the heart muscle (cardiomyopathy) or
    premature coronary artery disease. When post-mortem examinations fail to reveal
    such abnormalities, the term sudden arrhythmic death syndrome (SAD) is applied.

    Diagnosis: Anyone who feels faint, giddy or has a blackout or palpitations
    should have this investigated. An X-ray will show whether the heart has become
    enlarged, or if fluid is accumulating in the lungs. An ECG, which records the
    electrical activity of the heart and can reveal any muscle thickening or damage,
    is needed for a firm diagnosis of cardiomyopathy. Sometimes an athlete's heart
    may mimic cardiomyopathy because it is so developed - an ECG will help clarify

    Magnetic resonance imaging (MRI) is sometimes used to provide additional

    Other investigations may include cardiac catheterisation to measure pressure
    in the different chambers of the heart and to obtain a biopsy of the heart
    muscle (particularly in cases of restrictive cardiomyopathy): a catheter is
    inserted into the vein in the groin or neck and threaded into the heart. For
    people with serious rhythm disorders, electrophysiological studies may be
    necessary. Here electrode catheters are inserted, which then emit electrical
    impulses to provoke an arrythmia.

    When someone is diagnosed with cardiomyopathy, non-invasive tests (ECG and
    echo), should be offered to their relatives. Gene tests are being developed, but
    no simple test exists at present.

    Treatment: There is no cure for cardiomyopathy and treatment is aimed at
    preventing complications and improving symptoms. For the majority who have few

    or no symptoms treatment is not given.

    Drug treatments for cardiomyopathy include beta-blockers, ACE inhibitors and
    anticoagulants. Beta-blockers block the stimulating effect of adrenaline,
    slowing the heart rate and reducing the demands on the heart. Beta-blockers
    cannot be given to patients with bronchitis or asthma because they make
    breathing more difficult. Other possible side-effects include cold hands and
    feet, aching leg muscles when walking, tiredness and occasionally impotence.

    ACE inhibitors work by dilating the blood vessels, which leads to a fall in
    blood pressure. This helps in cases of cardiomyopathy as it reduces the work the
    heart has to do to pump blood around the body (and prevents the heart from
    getting progressively bigger). Some patients on ACE inhibitors develop a
    troublesome cough, which may mean they have to stop taking medication. However,
    a newer class of drugs - Angiotensin II antagonists - may help in such cases.
    Anticoagulants are given to prevent blood clots forming in the chambers and then
    causing a stroke or pulmonary embolism.

    For people with hypertrophic cardiomyopathy, surgery can help relieve
    symptoms by removing some of the excess muscle.

    For patients at high risk of sudden death, implantable carrdioverter
    defibrillators may be used to monitor the heart's electrical activity. If a
    serious arrhythmia is detected, an electric shock will be delivered to the heart

    page 10). Pacemakers are indicated in people with slow heart rates or heart
    block (see

    page 10). In very advanced cases when medical therapy is ineffective the
    patient may be referred for transplantation.

    Incidence and mortality: Around one in 500 people is affected by
    hypertrophic cardiomyopathy; one in 1,000 has arrhythmogenic right ventricular
    cardiomyopathy and one in 1,000 has dilated cardiomyopathy, the Cardiomyopathy
    Association reports.

    New research/developments: The genes linked to various cardiomyopathies are
    now being identified, including 11 for hypertrophic cardiomyopathy, 15 for
    dilated cardiomyopathy and two for arrhythmogenic right ventricular
    cardiomyopathy. Once

    the pathways which cause muscle cell damage are identified, scientists will

    able to produce drugs that can interfere or prevent the disease developing
    and progressing. "Once we understand the genetic basis of cardiomyopathy we can
    begin to offer clinical DNA testing," McKenna says. "This would make it much
    easier to evaluate families."

    In the US and Italy it is mandatory for all competitive athletes to be
    screened for cardiomyopathy, and in the UK the organisation Cardiac Risk in the
    Young (CRY)

    is campaigning for all people involved in sport to be offered a cardiac
    evaluation. The widespread availability of genetic tests would make screening
    easier to implement in the UK.

    Recognising that it can be difficult for patients in different parts of the
    country to get to see cardiologists with a special interest in cardiomyopathy,
    the Cardiomyopathy Association is leading a project to set up regional clinics
    to give cardiologists and their patients access to specialists at the Heart
    Hospital in London through telemedicine links. "This facility will provide
    support not only for echo cardiographic assessment, but also for genetic
    counselling and clinical management of patients," McKenna says.

    European comparisons: The incidence of cardiomyopathy is the same for most
    European countries, although it appears that more people are affected by
    arrhythmogenic right ventricular cardiomyopathy in Venice and parts of Greece
    than in other parts of Europe.



    Cardiomyopathy Association,

    helpline 0800-0181 024, provides information and support to people affected
    by cardiomyopathy


    Cardiac Risk in the Young. Offers screening for young people and counselling
    for loss of a family member, 01737 363222 www.sadsuk.org

    Sudden Adult Death Trust provides information and support to families who
    have experienced the sudden unexpected death of a relation or friend from a
    cardiac problem.


    Will I need exercise tests or monitoring?

    What sort of anaesthetic will be given for electrical cardioversion?

    Is there a risk of heart block in my case?

    LOAD-DATE: November 11, 2003

Today's Birthdays